| Identification | Back Directory | [Name]
5H-Pyrimido[4,5-e][1,4]diazepin-5-one, 2-(ethylamino)-6,7,8,9-tetrahydro-9-methyl-6-[3-[(1S)-3-(methylamino)-1-(2-thienyl)propoxy]phenyl]- | [CAS]
2143584-82-9 | [Synonyms]
Cavα2δ1&NET-IN-3
5H-Pyrimido[4,5-e][1,4]diazepin-5-one, 2-(ethylamino)-6,7,8,9-tetrahydro-9-methyl-6-[3-[(1S)-3-(methylamino)-1-(2-thienyl)propoxy]phenyl]- | [Molecular Formula]
C24H30N6O2S | [MOL File]
2143584-82-9.mol | [Molecular Weight]
466.6 |
| Hazard Information | Back Directory | [Uses]
Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the subunit α2δ of voltage-gated calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has Kis of 100-500 nM for human α2δ-1 subunit of Cav2.2 calcium channel and NET, respectively[1]. | [IC 50]
Calcium Channel | [References]
[1] Félix CUEVAS-CORDOBéS, et al. Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions. WO2017191304A1. |
|
|